HEPHAISTOS-Pharma raises €2 million (seed) to accelerate the development of their ONCO-Boost treatment
Published on :
31/01/2024
31
January
Jan
01
2024
Altaïr Avocats has advised HEPHAISTOS-Pharma, a key player in the biotechnology sector, in its €2 million Seed fundraising. The deal will enable HEPHAISTOS-Pharma to advance the clinical development of their injectable immunostimulant ONCO-Boost.
Currently in development, ONCO-Boost is an innovative injectable immunostimulant designed to transform cold tumours, which are resistant to the immune system, into warm tumours, which are vulnerable to elimination. This breakthrough could radically transform the treatment of cancer, and positions HEPHAISTOS-Pharma as a future leader in immuno-oncology.
HEPHAISTOS-Pharma aims to establish, over time, strategic partnerships with Big Pharma in order to extend the applications of ONCO-Boost. The funds will enable HEPHAISTOS-Pharma to accelerate its clinical development, industrialise its manufacturing process and open a new subsidiary in Liège, Wallonia.
The fund-raising was orchestrated by Xista Science Ventures and the Fondation Fournier-Majoie, with the participation of Noshaq. It also benefited from the support of Angels Santé and historical investors.
The participants in this transaction:
Altaïr Avocats was involved in the:
Corporate with a team composed of: Philippe Beauregard, partner, and Jeanne Mucchielli, associate.
At the same time, the new investors were advised by Jones Day, represented by partner Jean-Gabriel Griboul and associate Gabriel Saint-Paul.
History
-
Précisions sur la contestation du refus des propositions d’engagements par l’Autorité de la concurrence
Published on : 16/02/2024 16 February Feb 02 2024Droit commercial / Droit de la concurrence
L’Autorité de la concurrence a pour mission de prévenir et sanctionner les pr...Source : www.lemag-juridique.com -
Fusions, apports et opérations assimilées : nouveau règlement ANC 2023-08
Published on : 15/02/2024 15 February Feb 02 2024Droit des sociétés / Fusions et acquisitions
À la suite de l’ordonnance transposant la directive européenne 2019/2121, l’A...Source : www.efl.fr -
Due diligences, plus longues et plus complexes
Published on : 08/02/2024 08 February Feb 02 2024Droit des sociétés / Fusions et acquisitions
Dans un contexte d’incertitudes qui rend les performances futures des entrepr...Source : www.lenouveleconomiste.fr -
Précisions sur l’agrément dans les SARL
Published on : 07/02/2024 07 February Feb 02 2024Droit des sociétés / Droit des sociétés commerciales et professionnelles
Dans une société à responsabilité limitée (SARL), la loi prévoit l’applicatio...Source : www.lemag-juridique.com -
WE POSITIVE INVEST 2 (ARKEA CAPITAL), WILLE FINANCE and SWEN CAPITAL complete the €8 million fundraising of Beedeez
Published on : 06/02/2024 06 February Feb 02 2024Deals EN
Altaïr Avocats has advised a consortium of investors, WE POSITIVE INVEST 2 (A... -
WE POSITIVE INVEST 2 (ARKEA CAPITAL), WILLE FINANCE et SWEN CAPITAL finalisent la levée de fonds de 8 millions d’euros de Beedeez
Published on : 06/02/2024 06 February Feb 02 2024
Altaïr Avocats a conseillé un consortium d'Investisseurs, WE POSITIVE INVEST... -
DISTRIBUTION NETWORK AND RESTRICTIONS ON INTERNET SALES
Published on : 06/02/2024 06 February Feb 02 2024Publications et Séminaires
After sentencing Mariage Frères (Decision 23-D-12 of 11 december 2023), to a... -
HEPHAISTOS-Pharma raises €2 million (seed) to accelerate the development of their ONCO-Boost treatment
Published on : 31/01/2024 31 January Jan 01 2024Deals EN
Altaïr Avocats has advised HEPHAISTOS-Pharma, a key player in the biotechnolo...
-
HEPHAISTOS-Pharma lève 2 millions d'euros (seed) pour accélérer le développement de leur traitement ONCO-Boost
Published on : 31/01/2024 31 January Jan 01 2024
Altaïr Avocats a conseillé HEPHAISTOS-Pharma, acteur-clé du secteur de la bio...